Cancer prevention clinical trials.
Prevention of cancer through interventions based on sound scientific research remains an important strategy of oncology research at the National Cancer Institute (NCI). Reducing the burden of cancer in the United States is focused on clinical investigations in medical settings and public health intervention research on cancer risk factors regarding lifestyle and diet. Chemoprevention research at the NCI has progressed systematically to identify potential agents that reduce cancer risk and to develop public health strategies that take advantage of basic research results. In addition, advances in our understanding of molecular targets and pathways and our use of new and emerging technologies have become important tools for oncology research. Priority areas for chemoprevention research, identified from experimental and clinical research, are investigated in clinical trials to determine their ability to reduce cancer risk in selected populations or in the general population. Priority areas discussed in this review are the relationship of the arachidonic acid pathway to carcinogenesis, lung cancer prevention in former smokers, breast cancer prevention, and prostate cancer prevention. In addition, two lifestyle factors that have potential to influence cancer risk-obesity and functionally enhanced foods-are discussed in the context of their link between clinical and public health-related research.
Greenwald
Peter
P
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7309, USA. pg37g@nih.gov
D016588:Anticarcinogenic Agents; D001943:Breast Neoplasms / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000639:trends*; D004032:Diet; D015444:Exercise; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control*; D008297:Male; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D012107:Research Design
D016588:Anticarcinogenic Agents